Advocacy at a Glance STEVEN GROSSMAN 8/23/19 Advocacy at a Glance STEVEN GROSSMAN 8/23/19 Appropriations Bills Face Unknown Fate in September Read More Advocacy at a Glance STEVEN GROSSMAN 8/15/16 Advocacy at a Glance STEVEN GROSSMAN 8/15/16 Key Congressional Decisions: CR or Omnibus; December or March Read More Advocacy at a Glance STEVEN GROSSMAN 5/13/16 Advocacy at a Glance STEVEN GROSSMAN 5/13/16 Senate Ag/FDA Appropriations to Be Marked Up May 17 and 19 Read More Analysis and Commentary STEVEN GROSSMAN 4/22/16 Analysis and Commentary STEVEN GROSSMAN 4/22/16 The Start of the Califf Era Read More Advocacy at a Glance STEVEN GROSSMAN 4/22/16 Advocacy at a Glance STEVEN GROSSMAN 4/22/16 Califf Speech to Alliance a Huge Success Read More Membership Matters STEVEN GROSSMAN 4/15/16 Membership Matters STEVEN GROSSMAN 4/15/16 Upcoming Alliance Events Read More Membership Matters STEVEN GROSSMAN 4/8/16 Membership Matters STEVEN GROSSMAN 4/8/16 Significant Upcoming Alliance Events Read More Advocacy at a Glance STEVEN GROSSMAN 4/1/16 Advocacy at a Glance STEVEN GROSSMAN 4/1/16 FDA’s Generics Performance Report and more Read More Analysis and Commentary STEVEN GROSSMAN 3/4/16 Analysis and Commentary STEVEN GROSSMAN 3/4/16 Califf Debuts on Capitol Hill with Two Priorities Read More Advocacy at a Glance STEVEN GROSSMAN 3/4/16 Advocacy at a Glance STEVEN GROSSMAN 3/4/16 National Biomedical Research Act Introduced Read More Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Details on FDA’s Request for FY 17 FSMA Appropriations and more Read More Advocacy at a Glance STEVEN GROSSMAN 2/12/16 Advocacy at a Glance STEVEN GROSSMAN 2/12/16 President’s FY 17 Budget Request for FDA: Disappointing and Alarming and more Read More Advocacy at a Glance STEVEN GROSSMAN 2/5/16 Advocacy at a Glance STEVEN GROSSMAN 2/5/16 Obama-Proposed “Cancer Moonshot” Includes Monies for FDA Read More Analysis and Commentary STEVEN GROSSMAN 1/29/16 Analysis and Commentary STEVEN GROSSMAN 1/29/16 The Prompt Confirmation of a New Commissioner Read More Advocacy at a Glance STEVEN GROSSMAN 1/29/16 Advocacy at a Glance STEVEN GROSSMAN 1/29/16 Senator Murray Wants FDA at “Full Throttle;” Pushes Mandatory FDA Funding and more Read More Advocacy at a Glance STEVEN GROSSMAN 1/23/16 Advocacy at a Glance STEVEN GROSSMAN 1/23/16 Federal Deficit Certain to Grow Over Next 10 Years and more Read More Advocacy at a Glance STEVEN GROSSMAN 1/15/16 Advocacy at a Glance STEVEN GROSSMAN 1/15/16 FY 17 Appropriations Process to Be Speeded Up and more Read More Advocacy at a Glance STEVEN GROSSMAN 12/18/15 Advocacy at a Glance STEVEN GROSSMAN 12/18/15 FY 16 Appropriations Nears Finale and more Read More Advocacy at a Glance STEVEN GROSSMAN 12/11/15 Advocacy at a Glance STEVEN GROSSMAN 12/11/15 Senate HELP Committee Vote on FDA Commissioner Nomination Possible in January and more Read More Advocacy at a Glance STEVEN GROSSMAN 11/20/15 Advocacy at a Glance STEVEN GROSSMAN 11/20/15 Califf Hearing Appears to Have Gone Well and more Read More Older Posts
Advocacy at a Glance STEVEN GROSSMAN 8/23/19 Advocacy at a Glance STEVEN GROSSMAN 8/23/19 Appropriations Bills Face Unknown Fate in September Read More
Advocacy at a Glance STEVEN GROSSMAN 8/15/16 Advocacy at a Glance STEVEN GROSSMAN 8/15/16 Key Congressional Decisions: CR or Omnibus; December or March Read More
Advocacy at a Glance STEVEN GROSSMAN 5/13/16 Advocacy at a Glance STEVEN GROSSMAN 5/13/16 Senate Ag/FDA Appropriations to Be Marked Up May 17 and 19 Read More
Analysis and Commentary STEVEN GROSSMAN 4/22/16 Analysis and Commentary STEVEN GROSSMAN 4/22/16 The Start of the Califf Era Read More
Advocacy at a Glance STEVEN GROSSMAN 4/22/16 Advocacy at a Glance STEVEN GROSSMAN 4/22/16 Califf Speech to Alliance a Huge Success Read More
Membership Matters STEVEN GROSSMAN 4/15/16 Membership Matters STEVEN GROSSMAN 4/15/16 Upcoming Alliance Events Read More
Membership Matters STEVEN GROSSMAN 4/8/16 Membership Matters STEVEN GROSSMAN 4/8/16 Significant Upcoming Alliance Events Read More
Advocacy at a Glance STEVEN GROSSMAN 4/1/16 Advocacy at a Glance STEVEN GROSSMAN 4/1/16 FDA’s Generics Performance Report and more Read More
Analysis and Commentary STEVEN GROSSMAN 3/4/16 Analysis and Commentary STEVEN GROSSMAN 3/4/16 Califf Debuts on Capitol Hill with Two Priorities Read More
Advocacy at a Glance STEVEN GROSSMAN 3/4/16 Advocacy at a Glance STEVEN GROSSMAN 3/4/16 National Biomedical Research Act Introduced Read More
Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Details on FDA’s Request for FY 17 FSMA Appropriations and more Read More
Advocacy at a Glance STEVEN GROSSMAN 2/12/16 Advocacy at a Glance STEVEN GROSSMAN 2/12/16 President’s FY 17 Budget Request for FDA: Disappointing and Alarming and more Read More
Advocacy at a Glance STEVEN GROSSMAN 2/5/16 Advocacy at a Glance STEVEN GROSSMAN 2/5/16 Obama-Proposed “Cancer Moonshot” Includes Monies for FDA Read More
Analysis and Commentary STEVEN GROSSMAN 1/29/16 Analysis and Commentary STEVEN GROSSMAN 1/29/16 The Prompt Confirmation of a New Commissioner Read More
Advocacy at a Glance STEVEN GROSSMAN 1/29/16 Advocacy at a Glance STEVEN GROSSMAN 1/29/16 Senator Murray Wants FDA at “Full Throttle;” Pushes Mandatory FDA Funding and more Read More
Advocacy at a Glance STEVEN GROSSMAN 1/23/16 Advocacy at a Glance STEVEN GROSSMAN 1/23/16 Federal Deficit Certain to Grow Over Next 10 Years and more Read More
Advocacy at a Glance STEVEN GROSSMAN 1/15/16 Advocacy at a Glance STEVEN GROSSMAN 1/15/16 FY 17 Appropriations Process to Be Speeded Up and more Read More
Advocacy at a Glance STEVEN GROSSMAN 12/18/15 Advocacy at a Glance STEVEN GROSSMAN 12/18/15 FY 16 Appropriations Nears Finale and more Read More
Advocacy at a Glance STEVEN GROSSMAN 12/11/15 Advocacy at a Glance STEVEN GROSSMAN 12/11/15 Senate HELP Committee Vote on FDA Commissioner Nomination Possible in January and more Read More
Advocacy at a Glance STEVEN GROSSMAN 11/20/15 Advocacy at a Glance STEVEN GROSSMAN 11/20/15 Califf Hearing Appears to Have Gone Well and more Read More
